- Home
- PMVP vs HOWL Comparison
PMVP vs HOWL Comparison
Compare PMVP & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- HOWL
- Stock Information
- Founded
- PMVP 2013
- HOWL 2017
- Country
- PMVP United States
- HOWL United States
- Employees
- PMVP N/A
- HOWL N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- HOWL Health Care
- Exchange
- PMVP Nasdaq
- HOWL Nasdaq
- Market Cap
- PMVP 55.1M
- HOWL 53.4M
- IPO Year
- PMVP 2020
- HOWL 2021
- Fundamental
- Price
- PMVP $1.25
- HOWL $1.25
- Analyst Decision
- PMVP Strong Buy
- HOWL Strong Buy
- Analyst Count
- PMVP 1
- HOWL 3
- Target Price
- PMVP $5.00
- HOWL $8.33
- AVG Volume (30 Days)
- PMVP 230.0K
- HOWL 549.7K
- Earning Date
- PMVP 08-07-2025
- HOWL 08-07-2025
- Dividend Yield
- PMVP N/A
- HOWL N/A
- EPS Growth
- PMVP N/A
- HOWL N/A
- EPS
- PMVP N/A
- HOWL N/A
- Revenue
- PMVP N/A
- HOWL $1,143,000.00
- Revenue This Year
- PMVP N/A
- HOWL N/A
- Revenue Next Year
- PMVP N/A
- HOWL N/A
- P/E Ratio
- PMVP N/A
- HOWL N/A
- Revenue Growth
- PMVP N/A
- HOWL N/A
- 52 Week Low
- PMVP $0.81
- HOWL $0.60
- 52 Week High
- PMVP $1.82
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- PMVP 64.21
- HOWL 45.36
- Support Level
- PMVP $0.96
- HOWL $1.03
- Resistance Level
- PMVP $1.36
- HOWL $1.10
- Average True Range (ATR)
- PMVP 0.09
- HOWL 0.07
- MACD
- PMVP 0.01
- HOWL -0.02
- Stochastic Oscillator
- PMVP 72.22
- HOWL 22.81
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.